Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial
Sarah A. Holstein(University of Nebraska Medical Center), Philip L. McCarthy(Roswell Park Comprehensive Cancer Center), Steven M. Devine(National Marrow Donor Program), Molly Boyd(Mayo Clinic), Muzaffar H. Qazilbash(The University of Texas MD Anderson Cancer Center), Craig C. Hofmeister(The Ohio State University), Sin‐Ho Jung(Duke University), Ravi Vij(Washington University in St. Louis), Edward A. Stadtmauer(University of Pennsylvania), Teresa Gentile(SUNY Upstate Medical University), Kouros Owzar(Duke University), Luis Isola(Mount Sinai Medical Center), Parameswaran Hari(Medical College of Wisconsin), Kenneth C. Anderson(Dana-Farber Cancer Institute), Asad Bashey, Natalie S. Callander(University of Wisconsin–Madison), Paul G. Richardson(Harvard University), Koen van Besien(University Hospitals of Cleveland), Hani Hassoun(Memorial Sloan Kettering Cancer Center), Brian McClune(University of Minnesota Medical Center), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Daniel J. Weisdorf(University of Minnesota), Thomas Martin(University of California, San Francisco), Richard T. Maziarz(Oregon Health & Science University), Marcelo C. Pasquini(Cleveland Clinic), Jan S. Moreb(University of Florida), Mary M. Horowitz(Medical College of Wisconsin), Chen Jiang, Marcia Wilson(Mayo Clinic), Scott E. Smith(Loyola University Medical Center), Thomas C. Shea(University of North Carolina at Chapel Hill), Charles Linker(University of California, San Francisco), Robert Schlossman(University of Leeds), Cesar Rodriguez(Wake Forest University), Chelsea Schultz(Mayo Clinic), Heather Landau(Memorial Sloan Kettering Cancer Center), David D. Hurd(Duke University), Vera Hárs
Cited by 172
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k